CRVO Stock Overview
A biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
CervoMed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.77 |
| 52 Week High | US$26.38 |
| 52 Week Low | US$5.85 |
| Beta | 0 |
| 11 Month Change | -24.69% |
| 3 Month Change | -30.56% |
| 1 Year Change | 9.67% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 41.90% |
Recent News & Updates
Shareholder Returns
| CRVO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.3% | -10.3% | -2.1% |
| 1Y | 9.7% | 13.6% | 29.6% |
Return vs Industry: CRVO underperformed the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: CRVO underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| CRVO volatility | |
|---|---|
| CRVO Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRVO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CRVO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 8 | John Alam | www.cervomed.com |
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer’s diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials.
CervoMed Inc. Fundamentals Summary
| CRVO fundamental statistics | |
|---|---|
| Market cap | US$88.89m |
| Earnings (TTM) | -US$11.95m |
| Revenue (TTM) | US$10.07m |
8.8x
P/S Ratio-7.4x
P/E RatioIs CRVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRVO income statement (TTM) | |
|---|---|
| Revenue | US$10.07m |
| Cost of Revenue | US$14.57m |
| Gross Profit | -US$4.50m |
| Other Expenses | US$7.45m |
| Earnings | -US$11.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.45 |
| Gross Margin | -44.71% |
| Net Profit Margin | -118.68% |
| Debt/Equity Ratio | 0% |
How did CRVO perform over the long term?
See historical performance and comparison